UniCel DxI 800 Access Immunoassay System
Fast throughput means time-saving results for the high-volume lab
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Great
Immunoassay
Very good instrument. User friendly. Will recommend to others also.
Review Date: 12 Feb 2024 | Beckman Coulter Diagnostics
Overall a really solid analyzer
Clinical Chemistry/Immunosaasy
The DxI 800 is a work horse for us. We have 2 analysers on an automation line that run 24/7. They have very little down time. There is a large test menu. Maintenance can be a little time consuming. hsTroponin assay is not the greatest. Lots of fliers in the low end.
Review Date: 13 Nov 2023 | Beckman Coulter Diagnostics
high-throughput analyzer for a mid range laboratory.
Immunoassay analyzer with a throughput of 400 tests per hour.
Faster and reproducible results. Easy maintenance. High throughput.
Review Date: 19 Jul 2022 | Beckman Coulter Diagnostics
Great results.
Hormones and tumor markers
Achieve great results, stable reagents.
Review Date: 7 Jul 2021 | Beckman Coulter Diagnostics
DXI 800 is a very good instrument from Beckman Coulter.
Patient care
Very good product, excellent backup support, on time service and value for money.
Review Date: 6 Jun 2021 | Beckman Coulter Diagnostics
Fast throughput means time-saving results for the high-volume lab
Accelerate immunoassay time-to-results in your high-volume lab with the UniCel DxI 800 Access Immunoassay System. Run up to 400 tests per hour and handle even the most demanding workloads with ease. Count on the DxI 800 to be ready when you are, with low maintenance and improved reliability. The DxI 800 is simple enough for technologists of all skill levels to use, with industry-leading intuitive user interfaces and “load-and-go” simplicity that frees up staff for higher-value work—no pausing or standby time required.
Beckman Coulter offers $4/high-throughput antigen test to support U.S. government initiative to expand COVID-19 testing
The company is set to support the $12 billion expansion in COVID-19 testing as vaccinations increase
Beckman Coulter launches its Access SARS-CoV-2 IgM assay in countries accepting the CE mark
The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR
MIS-C detection: Beckman Coulter partners with BARDA in rapid diagnostic for pediatric complication of SARS-CoV-2
The partnership aims to expand existing Monocyte Distribution Width (MDW) hematology-based biomarker to potentially aid in the rapid detection of MIS-C
